+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class, and Therapy - Global Opportunity Analysis and Industry Forecast, 2018-2025

  • ID: 4612779
  • Report
  • July 2018
  • Region: Global
  • 205 pages
  • Allied Analytics LLP
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
The prostate is a walnut-sized gland that surrounds the urethra in the male reproductive system. The main function of this gland is to secrete a fluid, which mixes with the fluids from other glands and sperm cells from the testicles to generate semen. Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland. This increase blocks the urine flow from the bladder, which results in increased urination frequency at night, urinary hesitancy, and urinary retention. BPH significantly influences the patient’s quality of life, owing to symptoms, such as urine leakage and nocturia. If untreated for a long duration, it results in more serious health issues, such as bladder damage, bladder stones, kidney damage, and urinary tract infections (UTIs).

The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 60 and above. The other factors boosting the market growth include growth in awareness related to urological disorders and prostate cancer and rise in the number of global benign prostatic hyperplasia patients. However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.

The global benign prostatic hyperplasia therapeutics market is segmented into therapeutic class, therapy, and region. On the basis of therapeutic class, the market is categorized into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. As per therapy, the market is bifurcated into mono drug therapy and combination drug therapy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).

KEY BENEFITS

The study provides an in-depth analysis of the global benign prostatic hyperplasia therapeutics market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
A comprehensive analysis of factors that drive and restrict the market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on global and regional scales are provided.
The profiles of key players and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key market segments

By Therapeutic Class

Alpha blocker
5-Alpha reductase inhibitor
Phosphodiesterase-5 inhibitor
Others

By Therapy

Mono drug therapy
Combination drug therapy

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Abbott Laboratories
Allergan plc
Astellas Pharma, Inc.
Boehringer Ingelheim Pharma GmbH & Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Limited
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porters Five Forces analysis
3.4.1. Bargaining power of buyers
3.4.2. Bargaining power of suppliers
3.4.3. Threat of substitution
3.4.4. Threat of new entrant
3.4.5. Competitive rivalry
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in in geriatric population
3.5.1.2. Rise in prevalence of benign prostatic hyperplasia
3.5.1.3. Growth in the awareness related to urological disorders and prostate cancer
3.5.2. Restraints
3.5.2.1. High preferences for minimally invasive surgical therapies
3.5.3. Opportunities
3.5.3.1. Large number of products in pipeline
3.5.3.2. Opportunities in emerging economies
3.5.4. Impact analyses
3.6. Clinical trials

CHAPTER 4: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Alpha Blockers
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. 5-Alpha Reductase Inhibitors
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Phosphodiesterase 5 Inhibitor
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY
5.1. Overview
5.1.1. Market size and forecast
5.2. Mono Drug Therapy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Combination Drug Therapy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America benign prostatic hyperplasia therapeutics market, by country
6.2.2.1. U.S.
6.2.2.1.1. Market size and forecast, by therapeutic class
6.2.2.1.2. Market size and forecast, by therapy
6.2.2.2. Canada
6.2.2.2.1. Market size and forecast, by therapeutic class
6.2.2.2.2. Market size and forecast, by therapy
6.2.2.3. Mexico
6.2.2.3.1. Market size and forecast, by therapeutic class
6.2.2.3.2. Market size and forecast, by therapy
6.2.3. North America market size and forecast, by therapeutic class
6.2.4. North America market size and forecast, by therapy
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Market size and forecast, by therapeutic class
6.3.2.1.2. Market size and forecast, by therapy
6.3.2.2. France
6.3.2.2.1. Market size and forecast, by therapeutic class
6.3.2.2.2. Market size and forecast, by therapy
6.3.2.3. UK
6.3.2.3.1. Market size and forecast, by therapeutic class
6.3.2.3.2. Market size and forecast, by therapy
6.3.2.4. Italy
6.3.2.4.1. Market size and forecast, by therapeutic class
6.3.2.4.2. Market size and forecast, by therapy
6.3.2.5. Spain
6.3.2.5.1. Market size and forecast, by therapeutic class
6.3.2.5.2. Market size and forecast, by therapy
6.3.3. Rest of Europe
6.3.3.1.1. Market size and forecast, by therapeutic class
6.3.3.1.2. Market size and forecast, by therapy
6.3.4. Europe market size and forecast, by therapeutic class
6.3.5. Europe market size and forecast, by therapy
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Market size and forecast, by therapeutic class
6.4.2.1.2. Market size and forecast, by therapy
6.4.2.2. China
6.4.2.2.1. Market size and forecast, by therapeutic class
6.4.2.2.2. Market size and forecast, by therapy
6.4.2.3. India
6.4.2.3.1. Market size and forecast, by therapeutic class
6.4.2.3.2. Market size and forecast, by therapy
6.4.2.4. Australia
6.4.2.4.1. Market size and forecast, by therapeutic class
6.4.2.4.2. Market size and forecast, by therapy
6.4.2.5. South Korea
6.4.2.5.1. Market size and forecast, by therapeutic class
6.4.2.5.2. Market size and forecast, by therapy
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Market size and forecast, by therapeutic class
6.4.2.6.2. Market size and forecast, by therapy
6.4.3. Asia-Pacific market size and forecast, by therapeutic class
6.4.4. Asia-Pacific market size and forecast, by therapy
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Market size and forecast, by therapeutic class
6.5.2.1.2. Market size and forecast, by therapy
6.5.2.2. Saudi Arabia
6.5.2.2.1. Market size and forecast, by therapeutic class
6.5.2.2.2. Market size and forecast, by therapy
6.5.2.3. South Africa
6.5.2.3.1. Market size and forecast, by therapeutic class
6.5.2.3.2. Market size and forecast, by therapy
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Market size and forecast, by therapeutic class
6.5.2.4.2. Market size and forecast, by therapy
6.5.3. LAMEA market size and forecast, by therapeutic class
6.5.4. LAMEA market size and forecast, by therapy

CHAPTER 7: COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. Allergan plc
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance
7.3. Astellas Pharma Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. Boehringer Ingelheim Pharma GmbH & Co. KG
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance
7.5. Eli Lilly and Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.6. GlaxoSmithKline plc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.7. Merck & Co., Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Pfizer Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.9. Sanofi
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Teva Pharmaceutical Industries Limited
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
According to a new report, titled, Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class and Therapy: Global Opportunity Analysis and Industry Forecast, 2018-2025,the market was valued at $10,689 million in 2017, and is projected to reach $20,097 million in 2025, registering a CAGR of 8.1% from 2018 to 2025.

Benign prostatic hyperplasia (BPH) is a medical condition in which a males prostate gland size increases abnormally. This condition results in problems to start urition, weak urine stream, ibility to empty the uriry bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes mely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor. These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.

Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.

The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.

The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combition drug therapy segment is anticipated to record a high CAGR during the forecast period.

Key Findings of the Benign Prostatic Hyperplasia Therapeutics Market:

The phosphodiesterase-5 inhibitor segment accounted for nearly one-sixth share of the global benign prostatic hyperplasia therapeutics market in 2017.
The mono drug therapy segment is expected to grow at a CAGR of 7.6% from 2018 to 2025.
Europe accounted for around one-third share of the global market in 2017.
LAMEA is expected to provide lucrative market growth opportunities and grow at a CAGR of 9.6% from 2018 to 2025.

North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017, and is expected to domite the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.
Note: Product cover images may vary from those shown
5 of 5
  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma, Inc.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Limited
Note: Product cover images may vary from those shown
6 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll